Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

by · The Markets Daily

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Free Report) was the target of a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 246,970 shares, a growth of 252.3% from the May 14th total of 70,108 shares. Approximately 1.8% of the company’s stock are short sold. Based on an average daily volume of 112,419 shares, the short-interest ratio is currently 2.2 days.

Lixte Biotechnology Trading Down 14.6%

Shares of LIXT traded down $1.06 during midday trading on Friday, hitting $6.19. 871,824 shares of the company’s stock traded hands, compared to its average volume of 211,115. Lixte Biotechnology has a 1 year low of $0.64 and a 1 year high of $7.51. The firm’s fifty day moving average is $4.80 and its 200-day moving average is $3.92. The stock has a market capitalization of $92.97 million, a price-to-earnings ratio of -5.48 and a beta of 1.27.

Lixte Biotechnology (NASDAQ:LIXT – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) EPS for the quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on LIXT. Weiss Ratings downgraded Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 26th. Wall Street Zen raised Lixte Biotechnology to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Read Our Latest Research Report on LIXT

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Federation des caisses Desjardins du Quebec increased its stake in Lixte Biotechnology by 83.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after purchasing an additional 42,530 shares in the last quarter. Renaissance Technologies LLC increased its stake in Lixte Biotechnology by 47.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after purchasing an additional 34,350 shares in the last quarter. DRW Securities LLC increased its stake in Lixte Biotechnology by 11.6% during the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after purchasing an additional 5,645 shares in the last quarter. Geode Capital Management LLC increased its stake in Lixte Biotechnology by 25.9% during the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after purchasing an additional 10,722 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Lixte Biotechnology during the 4th quarter valued at approximately $57,000. Institutional investors and hedge funds own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

(Get Free Report)

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.

Featured Articles